Compare · ABT vs ONC
ABT vs ONC
Side-by-side comparison of Abbott Laboratories (ABT) and BeOne Medicines Ltd. (ONC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ONC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $157.69B, about 5.1x ONC ($30.70B).
- ONC has been more active in the news (35 items in the past 4 weeks vs 5 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 6 for ONC).
- Company
- Abbott Laboratories
- BeOne Medicines Ltd.
- Price
- -
- -
- Market cap
- $157.69B
- $30.70B
- 1M return
- +3.10%
- -
- 1Y return
- -34.47%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 5
- 35
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest ONC
- SEC Form 144 filed by BeOne Medicines Ltd.
- President and COO Wu Xiaobin sold $361,997 worth of American Depositary Shares (1,357 units at $266.76), closing all direct ownership in the company (SEC Form 4) to cover taxes
- SVP, General Counsel Lee Chan Henry sold $156,925 worth of American Depositary Shares (590 units at $265.98), closing all direct ownership in the company (SEC Form 4) to cover taxes
- Chief Executive Officer Oyler John sold $980,686 worth of American Depositary Shares (3,693 units at $265.55), closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- President, Global Head of R&D Wang Lai sold $310,236 worth of American Depositary Shares (1,169 units at $265.39), closing all direct ownership in the company (SEC Form 4) (tax liability)
- SEC Form 144 filed by BeOne Medicines Ltd.
- Principal Accounting Officer Ball Titus B. was granted 31,213 units of Ordinary Shares and sold $43,467 worth of American Depositary Shares (169 units at $257.20), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- President, Global Head of R&D Wang Lai was granted 118,625 units of Ordinary Shares and sold $197,318 worth of American Depositary Shares (756 units at $261.00), closing all direct ownership in the company (SEC Form 4) (tax liability)
- Chief Financial Officer Rosenberg Aaron was granted 71,175 units of Ordinary Shares and sold $162,637 worth of American Depositary Shares (631 units at $257.74), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- SVP, General Counsel Lee Chan Henry was granted 45,071 units of Ordinary Shares and sold $110,268 worth of American Depositary Shares (428 units at $257.63), closing all direct ownership in the company (SEC Form 4) (tax withholding)